Cerus Corporation (NASDAQ:CERS) is one of the best oversold growth stocks to invest in now.
BTIG upgraded Cerus Corporation (NASDAQ:CERS) to Buy from Neutral on May 1, reiterating a $4 price target
The rating update came after the company announced its financial results for fiscal Q1 2026, with total revenue for the quarter reaching $59.9 million, up 23% compared to the prior year period. Product revenue for fiscal Q1 2026 reached $53.7 million, reflecting a 24% growth over the prior year period. Cerus Corporation (NASDAQ:CERS) raised its full-year product revenue guidance range to $227 million – $231 million, reflecting 10% to 12% year-over-year increase.
Management attributed the strong start to 2026 to strength across the company’s business, in particular due to rising demand for its INTERCEPT Fibrinogen Complex. Cerus Corporation (NASDAQ:CERS) also announced a meaningful catalyst path in 2026, spanning anticipated regulatory, clinical, and pipeline milestones, which includes ongoing INTERCEPT RBC regulatory review in Europe, the Phase 3 RedeS readout in the U.S., and the planned U.S. PMA submission for its new INT200 illumination device.